| % of Cases treated with Hormone Therapy |
| All invasive xnmsc |
12.1% |
11.9% |
12.4% |
14.9% |
5.4% |
20.6% |
6.1% |
| Breast |
39.9% |
42.6% |
39.1% |
61.7% |
17.3% |
70.3% |
24.6% |
| Prostate |
43.2% |
38.7% |
45.7% |
52.1% |
20.4% |
60.3% |
14.9% |
| % of Cases treated with Brachytherapy |
| All invasive xnmsc |
0.9% |
1.2% |
0.9% |
NA |
NA |
1.7% |
1.1% |
| Breast |
0.0% |
0.1% |
0.0% |
NA |
NA |
0.0% |
0.2% |
| Prostate |
2.4% |
2.5% |
2.3% |
NA |
NA |
3.0% |
2.2% |
| % of Cases treated with Watch & Wait/Active Monitoring |
| All invasive xnmsc |
8.0% |
5.6% |
8.5% |
NA |
NA |
7.0% |
1.3% |
| Prostate |
24.2% |
17.4% |
25.8% |
NA |
NA |
22.1% |
4.2% |
| % of Cases treated with Palliative Care |
| All invasive xnmsc |
8.0% |
6.1% |
8.5% |
NA |
NA |
8.3% |
1.6% |
Printer-friendly version
